share_log

Senti Biosciences | 8-K: Current report

SEC announcement ·  May 18 05:18
Summary by Futu AI
Senti Biosciences, Inc. has announced a significant change in its executive leadership, effective May 14, 2024. Timothy Lu, M.D., Ph.D., who has been serving as both the Chief Executive Officer and President, stepped down from his role as President. Kanya Rajangam, M.D., Ph.D., previously the Head of Research and Development and Chief Medical Officer at Senti Biosciences, has been appointed as the new President. Dr. Lu will continue in his capacity as CEO of the company. Dr. Rajangam's extensive experience in the biopharmaceutical industry includes roles at various other companies such as Nkarta, Inc., Atara Biotherapeutics, and Nektar Therapeutics. Her appointment is part of a planned succession, and she has no familial or transactional relationships that require disclosure under SEC regulations. The terms of Dr. Rajangam's employment were detailed in an offer letter filed with the SEC in May 2023, which includes her compensation, bonus eligibility, stock options, and severance benefits.
Senti Biosciences, Inc. has announced a significant change in its executive leadership, effective May 14, 2024. Timothy Lu, M.D., Ph.D., who has been serving as both the Chief Executive Officer and President, stepped down from his role as President. Kanya Rajangam, M.D., Ph.D., previously the Head of Research and Development and Chief Medical Officer at Senti Biosciences, has been appointed as the new President. Dr. Lu will continue in his capacity as CEO of the company. Dr. Rajangam's extensive experience in the biopharmaceutical industry includes roles at various other companies such as Nkarta, Inc., Atara Biotherapeutics, and Nektar Therapeutics. Her appointment is part of a planned succession, and she has no familial or transactional relationships that require disclosure under SEC regulations. The terms of Dr. Rajangam's employment were detailed in an offer letter filed with the SEC in May 2023, which includes her compensation, bonus eligibility, stock options, and severance benefits.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.